pharma · Melanoma · HIV Infections
Bristol Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb is a pharma organization headquartered in STEINHAUSEN, CH. Primary therapeutic focus areas include Melanoma, HIV Infections, Prostate Cancer, Neoplasms by Site, Stomach Cancer. NovaPharmaNews links 4
Company details
- Status
- Public
- HQ
- 3401 Princeton Pike, Lawrence Township, NJ 08648, US
- Employees
- 38,146
- Programs
- 40
- Drugs
- 17
- Patents
- 25
Quick answer
Bristol-Myers Squibb is a pharma organization headquartered in STEINHAUSEN, CH. Primary therapeutic focus areas include Melanoma, HIV Infections, Prostate Cancer, Neoplasms by Site, Stomach Cancer. NovaPharmaNews links 40 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (21), phase 2 (12), phase 1 (7).
Company snapshot
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of
- 40 active pipeline program(s) linked via ClinicalTrials.gov.
- 25 US patent(s) indexed to this assignee profile.
- 40 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Bristol Myers Squibb. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Fierce Pharma Asia: Major Developments in Oncology and Workforce Changes
- deal
Analysis of BMS-Hengrui's $15B Deal and Its Implications
- approval
Fierce Pharma Asia: BMS-Hengrui's $15B Deal and More
- deal
BMS-Hengrui $15B Deal: Strategic Implications for Pharma Executives
- approval
This Week’s Biopharma News: New Approvals, Appeals, and AI
- approval
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
- trial_data
Cobenfy meets endpoint in Bristol Myers Squibb’s Alzheimer’s psychosis trial
Recent coverage
Cobenfy meets endpoint in Bristol Myers Squibb’s Alzheimer’s psychosis trial
Bristol Myers Squibb’s Cobenfy has reached a key milestone in Alzheimer’s psychosis, expanding the story beyond its approved schizophrenia use. Analysts should watch ADEPT-2 execution, enrollment changes, and whether the signal supports a broader development path.
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
This Week’s Biopharma News: New Approvals, Appeals, and AI
This week's biopharma news highlights significant FDA approvals for Datroway and Hepcludex, a key appeal win for Outlook regarding bevacizumab, and promising Phase 3 data for BioMarin's VOXZOGO. The evolving landscape also sees increased integration of AI in drug development and regulatory processes.
BMS-Hengrui $15B Deal: Strategic Implications for Pharma Executives
Bristol Myers Squibb's significant $15 billion partnership with Hengrui Pharma signals a strategic shift, leveraging China's R&D capabilities for early-stage assets. This deal offers valuable insights for pharmaceutical business development and investment teams.
Top assets
Lead pipeline drugs
- Marketed / approved
- Marketed / approved
- approved
- approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Bristol Myers Squibb.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Bristol Myers Squibb.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Bristol Myers Squibb?
-
Is Bristol Myers Squibb publicly traded?
-
What drugs does Bristol Myers Squibb develop or market?
-
What are the latest developments for Bristol Myers Squibb?
-
What therapeutic areas does Bristol Myers Squibb focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.